Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 702-708

  Kalyana Sundaram, Shanker ^a,b,c   Shankar, Sunita ^a,b   DeRoo, Scott ^a,b   Iyer, Matthew K ^a,b   Palanisamy, Nallasivam ^a,b   Chinnaiyan, Arul M ^a,b   Kumar Sinha, Chandan ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BHARATHIDASAN UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; MEMBRANE PROTEIN 49; S6 KINASE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; BREAST CANCER; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE FUSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84865214708     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12914     Document Type: Article

References (24)

1. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, and Stratton MR (2004). A census of human cancer genes. Nat Rev Cancer 4, 177-183.
2. Santarius T, Shipley J, Brewer D, Stratton MR, and Cooper CS (2010). A census of amplified and over expressed human cancer genes. Nat Rev Cancer 10, 59-64.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science 235, 177-182.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 344, 783-792.
5. Deming SL, Nass SJ, Dickson RB, and Trock BJ (2000). C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83, 1688-1695.
6. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, and Chen B (2005). EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18, 1027-1033.
7. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, and Reis-Filho JS (2007). FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9, R23.
8. Elsheikh S, Green AR, Aleskandarany MA, Grainge M, Paish CE, Lambros MB, Reis-Filho JS, and Ellis IO (2008). CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 109, 325-335.
9. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS, et al. (2011). Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res 21, 676-687.
10. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352.
11. Chinnaiyan AM and Palanisamy N (2010). Chromosomal aberrations in solid tumors. Prog Mol Biol Transl Sci 95, 55-94.
12. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, et al. (2011). Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17, 1646-1651.
13. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, and Brown PO (2002). Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99, 12963-12968.
14. Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, deJong PJ, Zhao S, Liebman M, and Weber BL (2004). 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 14, 179-187.
15. Mitelman F, Johansson B, and Mertens F (2010). Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. Cancer Genome Anatomy Project. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed March 2012.
16. Hyatt DC and Ceresa BP (2008). Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells. Exp Cell Res 314, 3415-3425.
17. Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi O-P, and Kallioniemi A (2000). Multiple genes at 17q23 undergo amplification and over expression in breast cancer. Cancer Res 60, 5340-5344.
18. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB, and James CD (1999). Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59, 1408-1411.
19. Monni O, Barlund M, Mousses S, Kononen J, Sauter G, Heiskanen M, Paavola P, Avela K, Chen Y, Bittner ML, et al. (2001). Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci USA 98, 5711-5716.
20. Sinclair CS, Rowley M, Naderi A, and Couch FJ (2003). The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 78, 313-322.
21. Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, and Ueno NT (2011). Gemcitabine overcomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of Akt. J Cancer 2, 435-442.
22. Maiello MR, D'Alessio A, De Luca A, Carotenuto A, Rachiglio AM, Napolitano M, Cito L, Guzzo A, and Normanno N (2007). AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat 102, 275-282.
23. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, and Holz MK (2009). S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 284, 6361-6369.
24. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefstrom J, Hautaniemi S, and Monni O (2008). Deciphering downstream gene targets of PI3K/mTOR/ p70S6K pathway in breast cancer. BMC Genomics 9, 348.